Percorrer por autor "Rodrigues, Marta"
A mostrar 1 - 1 de 1
Resultados por página
Opções de ordenação
- Nirsevimab Effectiveness Against RSV-Related Hospitalisations in Children Under 24 Months: A Test-Negative Case-Control Study in Portugal, 2024-2025Publication . Gaio, Vânia; Henriques, Camila; Lança, Miguel; Marques, Rita; Marques, Raquel; Rodrigues, Marta; Almeida, Sofia; Sousa, Beatriz; Freitas, Margarida; Amaral, Diana; Ferreira, Sara; Azevedo, Inês; von Hafe, Madalena; Gonçalves, Rafaela; Viseu, Regina; Bandeira, Teresa; Constant, Carolina; Malato, Madalena; Carvalho, Inês; Rodrigues, Jorge; Farinha, Margarida; Nunes, Teresa; Graça, Teresa; Gomez, Sofia; Soares, Sara; Neves, João Farela; Paixão, Paulo; Piscalho, Inês; Loureiro, Ana; Freitas, Cristina; Alves, José; Soares, Diana; Lopes, Paulo; Machado, Ausenda; Guiomar, Raquel; Rodrigues, Ana Paula; VigiRSV GroupWe assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)-related hospitalisation in eligible children (< 2 years) using a test-negative case-control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV-positive. Adjusted NE against RSV-related hospitalisation was 78.5% (95%CI: 59.3-89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.